克隆氏症市場：KOL 洞察

本報告探討了目前和新興的克隆氏症治療方法，包括 TNF 抑制劑、Entyvio、Stelara、Skyrizi、Rinvoq、Tremfya、Omvoh、Zeposia 和 Velsipity。對這些治療的功效、安全性和實用性進行了深入分析，並對可能影響未來處方趨勢的近期臨床試驗進行了深入分析。研究了生物相似藥和皮下製劑對市場的影響，並深入研究中度至重度克隆氏症的治療前景如何演變。

目錄

執行摘要

研究目的

• 已上市藥品
  • TNF 抑制劑 (Remicade, Humira, Cimzia)
  • Entyvio (vedolizumab; Takeda)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie)
  • Rinvoq (upadacitinib; AbbVie)
• 研究藥物
  • Tremfya (guselkumab; Johnson & Johnson Biotech)
  • Omvoh (mirikizumab; Lilly)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Velsipity (etrasimod; Pfizer)

未來治療趨勢

• 克隆氏症的未來治療策略可能傾向於合併治療、IL-23 抑制劑和口服治療
  • FMT 在 CD 中具有潛在的應用，但該策略很複雜且迄今為止尚未得到證實

附錄

Explore current and emerging treatments for Crohn's disease, including TNF inhibitors, Entyvio, Stelara, Skyrizi, Rinvoq, Tremfya, Omvoh, Zeposia, and Velsipity. This comprehensive report offers an in-depth analysis of the efficacy, safety, and usability of these treatments, as well as insights into recent clinical trials that could shape future prescribing trends. Examine the impact of biosimilars and subcutaneous formulations on the market, offering a detailed look at how the treatment landscape for moderate-to-severe Crohn's disease is evolving. Gain valuable knowledge on physician and payer preferences, the competitive positioning of pipeline products, and the overall market trends influencing drug therapies for Crohn's disease.

Key brands covered in this report:

• Remicade (infliximab)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Entyvio (vedolizumab)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)
• Rinvoq (upadacitinib)
• Tremfya (guselkumab)
• Omvoh (mirikizumab)
• Zeposia (ozanimod)
• Velsipity (etrasimod)

Key questions answered:

• Which CD therapies are preferred for different patient segments and lines of therapy?
• How do medical professionals perceive the efficacy, tolerability, and ease of administration of these therapies?
• Which recent clinical trials could significantly influence CD prescribing trends?
• How might the use of current and pipeline drugs change in the future?
• What must pipeline products demonstrate to compete with existing CD therapies?
• Which pipeline products are most promising and how might they impact the market?
• How will the CD treatment landscape evolve for different patient segments and therapy lines?

Companies:

AbbVie, Lilly, AstraZeneca, UCB, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Takeda, Johnson & Johnson.

Table of Contents

Executive summary

Research objectives

• Marketed drugs
  • TNF inhibitors (Remicade, Humira, Cimzia)
  • Entyvio (vedolizumab; Takeda)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie)
  • Rinvoq (upadacitinib; AbbVie)
• Pipeline drugs
  • Tremfya (guselkumab; Johnson & Johnson Biotech)
  • Omvoh (mirikizumab; Lilly)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Velsipity (etrasimod; Pfizer)

Future treatment trends

• Future treatment strategies for Crohn's could favour combinations, IL-23 inhibitors and oral therapies
  • FMT could have some applications in CD, but the strategy is complex and, to date, unproven

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe